Patent · US Active

Gene-therapy vectors for treating cardiomyopathy

US10501756B2 · kind B2 · utility

5Cited by

2References

5Claims

0Family size

Assignees

UNIVERSITÄTSKLINIKUM HAMBURG—EPPENDORF · DE
RUPRECHT - KARLS - UNIVERSITÄT HEIDELBERG · DE
Sorbonne Universite · FR
ASSOCIATION INSTITUT DE MYOLOGIE · FR

Inventors

Lucie Carrier · Hamburg, DE
Thomas Eschenhagen · Hamburg, DE
Thomas Voit · Gif-sur-Yvette, FR
Giulia Mearini · Hamburg, DE
Oliver Mueller · Heikendorf, DE
Doreen Stimpel · Hamburg, DE
Julia Mourot-Filiatre · Brasília, BR

Key dates

Filing date	Apr 17, 2014
Grant date	Dec 10, 2019
Priority date	—
Expiry date	Apr 17, 2034

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2830/008
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to a gene therapy vector which is useful in the treatment or prevention of hypertrophic cardiomyopathy in a subject in need thereof. The gene therapy vector of the invention comprises a nucleic acid sequence encoding a cardiac sarcomeric protein and a cardiomyocyte-specific promoter which is operably linked to said nucleic acid sequence. The invention furthermore relates to a cell which comprises the gene therapy vector. Pharmaceutical compositions which comprise the gene therapy vector and/or a cell comprising said vector are also provided. In another aspect, the invention relates to a method for treating or preventing hypertrophic cardiomyopathy in a subject by introducing the gene therapy vector of the invention into a subject in need of treatment.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.